Subscribe
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
2021
2020
2019
ASCO 2021 - Breast Cancer
ASCO 2021 Wrap-Up - Breast Cancer
ASCO 2020 - Lung Cancer
ASCO 2020 - Wrap Up
ASH 2020 - Multiple Myeloma
SABCS 2020 Highlights
ASH 2019 Post Wrap-Up
ASH 2019 Multiple Myeloma
Real-World Results of Bortezomib-Based Induction therapy in Newly Diagnosed MM
Conference Correspondent
,
ASH
Conference Correspondent
Researchers demonstrated that any reduction of dose intensity from 1.3 mg/m2 of bortezomib as a first-line treatment for untreated multiple myeloma patients is associated with inferior OS. Furthermore, it was suggested that the cumulative bortezomib dose be ≥20.75 mg for a better OS.
Read More ›
Bortezomib/Melphalan/Prednisone (VMP) Followed by Lenalidomide/Dexamethasone (Rd) Overcomes the Poor Prognosis of High-Risk Cytogenetics in Elderly Patients with NDMM
Conference Correspondent
,
ASH
Conference Correspondent
Researchers examined subset of elderly newly diagnosed myeloma patients from the GEM2010 trial and split the patients into 2 arms determined by their cytogenetic abnormalities (high risk and standard risk). Patients with 1q gains were shown to have similar outcomes to those without q1 gains when treated with bortezomib plus melphalan and prednisone, followed by lenalidomide and dexamethasone.
Read More ›
Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) Regimen for Transplant-Ineligible Patients with Newly Diagnosed MM
Conference Correspondent
,
ASH
Conference Correspondent
Modification of the current treatment regimen of RVD to “RVD-lite” provided better tolerability and enhanced clinical benefits in transplant-ineligible patients and proved to be particularly manageable in older populations, even with a wide variety of performance statuses at the beginning of the study.
Read More ›
Ixazomib plus Panobinostat and Dexamethasone in Heavily Pretreated Patients with RRMM
Conference Correspondent
,
ASH
Conference Correspondent
Investigators propose moving to a phase 2 evaluation after using a new treatment regimen that was well-tolerated in patients with progressive disease consisting of panobinostat at 20 mg 3 times a week every other week to ixazomib at target 4 mg weekly, 3 weeks on, 1 week off, with dexamethasone 20 mg on the day of and after ixazomib.
Read More ›
Ixazomib Monotherapy in RRMM Patients with Severe Renal Impairment or Those Requiring Hemodialysis
Conference Correspondent
,
ASH
Conference Correspondent
A pharmacokinetic and safety study of ixazomib in patients with severe renal impairment or end-stage renal disease requiring hemodialysis demonstrated that this patient subgroup requires dose modification of ixazomib due to a 38% higher, unbound systemic exposure. Administration of ixazomib may be administered without regard to the timing of dialysis.
Read More ›
Ixazomib plus Lenalidomide/Dexamethasone Improves Survival Outcomes in RRMM: Results of the Phase 3 Tourmaline-MM1 Study
Conference Correspondent
,
ASH
Conference Correspondent
This phase 3 study demonstrated that the all-oral therapy of ixazomib in combination with lenalidomide/dexamethasone significantly increased median PFS without a substantial increase in overall toxicity. A similar benefit was noted in patients with high-risk cytogenetics.
Read More ›
Final OS Analysis of Panorama 1 Trial of Panobinostat/Bortezomib/Dexamethasone in RRMM
Conference Correspondent
,
ASH
Conference Correspondent
Researchers present the final data for the secondary end point of overall survival across the entire study population of the phase 3 clinical trial PANORAMA 1, which evaluated panobinostat in combination with bortezomib and dexamethasone. Overall survival was not statistically significant.
Read More ›
Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM
Conference Correspondent
,
ASH
Conference Correspondent
The VISTA study demonstrated good tolerability of VMP; however, in a subsequent phase 2 trial, there was a higher rate of treatment discontinuation than expected. In this study, investigators demonstrated lowering the intensity of VMP proved to be both safe and effective for newly diagnosed multiple myeloma (NDMM).
Read More ›
Pomalidomide/Bortezomib/Low-Dose Dexamethasone in Lenalidomide-Refractory and Bortezomib-Exposed MM
Conference Correspondent
,
ASH
Conference Correspondent
A phase 1, multicenter study evaluated the use of PvD in patients with proteasome inhibitor–exposed and lenalidomide-refractory multiple myeloma to examine the maximum tolerated dose with secondary end points of safety, overall response rate, duration of response, and time to response.
Read More ›
Pomalidomide/Dexamethasone/Ixazomib versus Pomalidomide/Dexamethasone in Patients with RRMM
Conference Correspondent
,
ASH
Conference Correspondent
The phase 1/2 Alliance study sought to evaluate the safety and preliminary efficacy of the combination of ixazomib/pomalidomide/dexamethasone in patients with double-refractory multiple myeloma compared with the approved combination of pomalidomide/dexamethasone. Here, they report the phase 1 portion of the Alliance study.
Read More ›
Page 30 of 31
22
23
24
25
26
27
28
29
30
31
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION